Literature DB >> 15865930

C-Abl as a modulator of p53.

Yaara Levav-Cohen1, Zehavit Goldberg, Valentina Zuckerman, Tamar Grossman, Sue Haupt, Ygal Haupt.   

Abstract

P53 is renowned as a cellular tumor suppressor poised to instigate remedial responses to various stress insults that threaten DNA integrity. P53 levels and activities are kept under tight regulation involving a complex network of activators and inhibitors, which determine the type and extent of p53 growth inhibitory signaling. Within this complexity, the p53-Mdm2 negative auto-regulatory loop serves as a major route through which intra- and extra-cellular stress signals are channeled to appropriate p53 responses. Mdm2 inhibits p53 transcriptional activities and through its E3 ligase activity promotes p53 proteasomal degradation either within the nucleus or following nuclear export. Upon exposure to stress signals these actions of Mdm2 have to be moderated, or even interrupted, in order to allow sufficient p53 to accumulate in an active form. Multiple mechanisms involving a variety of factors have been demonstrated to mediate this interruption. C-Abl is a critical factor that under physiological conditions is required for the maximal and efficient accumulation of active p53 in response to DNA damage. C-Abl protects p53 by antagonizing the inhibitory effect of Mdm2, an action that requires a direct interplay between c-Abl and Mdm2. In addition, c-Abl protects p53 from other inhibitors of p53, such as the HPV-E6/E6AP complex, that inhibits and degrades p53 in HPV-infected cells. Surprisingly, the oncogenic form of c-Abl, the Bcr-Abl fusion protein in CML cells, also promotes the accumulation of wt p53. However, in contrast to the activation of p53 by c-Abl, its oncogenic form, Bcr-Abl, counteracts the growth inhibitory activities of p53 by modulating the p53-Mdm2 loop. Thus, it appears that by modulating the p53-Mdm2 loop, c-Abl and its oncogenic forms critically determine the type and extent of the cellular response to DNA damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865930     DOI: 10.1016/j.bbrc.2005.03.152

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

Review 2.  p53 and RAD9, the DNA Damage Response, and Regulation of Transcription Networks.

Authors:  Howard B Lieberman; Sunil K Panigrahi; Kevin M Hopkins; Li Wang; Constantinos G Broustas
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

3.  Involvement of c-Abl, p53 and the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 cells by exposure to blue light.

Authors:  Barbro S Westlund; Bolin Cai; Jilin Zhou; Janet R Sparrow
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

4.  Controlling Directed Protein Interaction Networks in Cancer.

Authors:  Krishna Kanhaiya; Eugen Czeizler; Cristian Gratie; Ion Petre
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

5.  The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.

Authors:  H Zhao; M-S Chen; Y-H Lo; S E Waltz; J Wang; P-C Ho; J Vasiliauskas; R Plattner; Y-L Wang; S-C Wang
Journal:  Oncogene       Date:  2013-04-01       Impact factor: 9.867

6.  c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.

Authors:  David L Waning; Jason A Lehman; Christopher N Batuello; Lindsey D Mayo
Journal:  J Biol Chem       Date:  2010-11-16       Impact factor: 5.157

7.  Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.

Authors:  Alessandro Furlan; Fabienne Lamballe; Venturina Stagni; Azeemudeen Hussain; Sylvie Richelme; Andrea Prodosmo; Anice Moumen; Christine Brun; Ivan Del Barco Barrantes; J Simon C Arthur; Anthony J Koleske; Angel R Nebreda; Daniela Barilà; Flavio Maina
Journal:  J Hepatol       Date:  2012-08-10       Impact factor: 25.083

8.  T cell survival and function requires the c-Abl tyrosine kinase.

Authors:  Isabelle Silberman; Ronit Vogt Sionov; Valentina Zuckerman; Sue Haupt; Zehavit Goldberg; Andreas Strasser; Zami S Ben-Sasson; Michal Baniyash; Anthony J Koleske; Ygal Haupt
Journal:  Cell Cycle       Date:  2008-12-23       Impact factor: 4.534

9.  Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.

Authors:  Ronald L Paquette; John Nicoll; Meenal Chalukya; Lucas Gondek; Monika Jasek; Charles L Sawyers; Neil P Shah; Jaroslaw Maciejewski
Journal:  Leuk Res       Date:  2009-10-04       Impact factor: 3.156

Review 10.  Role of ABL family kinases in cancer: from leukaemia to solid tumours.

Authors:  Emileigh K Greuber; Pameeka Smith-Pearson; Jun Wang; Ann Marie Pendergast
Journal:  Nat Rev Cancer       Date:  2013-07-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.